Australia-based Immutep and licensing partner, GlaxoSmithKline, have discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis.
The plug was pulled by GSK based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial’s data review committee. Immutep’s R&D collaboration with GSK, which dates back to 2010, remains in place and GSK2831781 continues to be under an exclusive license with GSK. The experimental treatment has also been explored in another autoimmune disease beyond ulcerative colitis, including psoriasis.
GSK says it will continue to assess the efficacy and safety data to determine next steps for the GSK2831781 development program.
Earlier this week, a lung cancer drug being co-developed by GSK and Merck KGaA failed a late-stage trial. The trial results were a major setback for the partner who are developing the drug under a deal potentially worth up to $4.5 billion.
Read the Immutep press release
